histamine

Small moleculeapproved

Approved

Mar 13, 1924

Histamine is a depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and a centrally acting neurotransmitter. Phosphate salt of jistamine was used as a diagnostic aid for evaluation of gastric acid secretory function. In addition, this compound is used as a positive control in evaluation of allergenic (immediate hypersensitivity or "Type I") skin testing. In addition, histamine is being studied for treatment of multiple sclerosis. It was approved, that histamine physiological functions are mediated by four 7-transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacological intervention. The receptors display molecular heterogeneity and constitutive activity. H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R led to the development of H2R-antagonists that revolutionized stomach ulcer treatment. The H3R is an auto receptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons. The H4R occurs on immuncompetent cells and the development of anti-inflammatory drugs is anticipated. — NCATS

Clinical trial activity

57 trials · 38 clinical orgs · 4 marketing orgs

Phase 1
6
Phase 2
14
Phase 3
7
Phase 4
4

Earliest trial started Jul 1, 1998 (NCT00003991)

Timeline

1920s

  1. Mar 13, 1924

    Jubilant Innovation Ltd. — Earliest FDA Approval

  2. Mar 13, 1924

    Jubilant Innovation Ltd. — NDA Secondary Org

  3. Mar 13, 1924

    Jubilant Innovation Ltd. — NDA Organization

1930s

  1. Apr 25, 1939

    Eli Lilly — NDA Secondary Org

1950s

  1. Sep 29, 1950

    ALK-Abello, S.A. — NDA Secondary Org

1990s

  1. Feb 14, 1992

    Nielsen BioSciences, Inc. — NDA Secondary Org

  2. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • HRH1 agonist

    Positive control for allegy test

  • Unspecified targetOTHER

    Topical analgesic

    Mechanism_for_indication: Minor aches and pains.

  • Unspecified targetOTHER

    Immunoprotectant

    Mechanism_for_indication: Acute myeloid leukemia.

Approval history

  • approvedMar 13, 1924

Chemistry & pharmacology

Loading structure…

SMILES

NCCc1c[nH]cn1.O=P(O)(O)O.O=P(O)(O)O
Mol. weight
307.14 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 1h-imidazole-4-ethanamine
  • 1h-imidazole-4-ethanamine
  • 2-(4-imidazolyl)ethylamine
  • 2-(4-imidazolyl)ethylamine
  • 4-imidazoleethylamine
  • 4-imidazoleethylamine
  • 5-imidazoleethylamine
  • 5-imidazoleethylamine
  • 5-imidazoleethylamine
  • beta-aminoethylglyoxaline
  • beta-aminoethylglyoxaline
  • beta-aminoethylimidazole
  • beta-aminoethylimidazole
  • ceplene
  • ceplene
  • ceplene
  • eramin
  • ergamine
  • ergotidine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine
  • histamine acid phosphate
  • histamine dihydrochloride
  • histamine dihydrochloride
  • histamine dihydrochloride
  • histamine dihydrochloride
  • histamine dihydrochloride
  • histamine dihydrocloride
  • histamine dihydrocloride
  • histamine diphosphate
  • histamine diphosphate
  • histamine glutarimide
  • histamine phosphate
  • histamine phosphate
  • histamine phosphate
  • histamine phosphate
  • histamine phosphate
  • histamine phosphate
  • histamine phosphate
  • positive skin test control-histamine
  • theramine
  • theramine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07255092N/ADec 1, 2025Aalborg University
NCT07203274N/ADec 1, 2025Aalborg University
NCT07247695N/ANov 3, 2025Aalborg University
NCT07122973N/ASep 17, 2025Aalborg University
NCT06503510N/AOct 1, 2024Aalborg University
NCT06503523N/ASep 1, 2024Aalborg University
NCT06245564N/AAug 20, 2024Aalborg University
NCT06470737N/AJul 1, 2024Aalborg University
NCT06328543N/AJul 1, 2024Aalborg University
NCT06340438N/AApr 27, 2024Aalborg University
NCT05810792Phase 2Apr 1, 2024University of Gothenburg
NCT06328530N/AApr 1, 2024Aalborg University
NCT06154824N/ADec 15, 2023Aalborg University
NCT06081946N/ADec 15, 2023Aalborg University
NCT06379542Phase 3Dec 4, 2023Valenta Pharm JSC
NCT06081998N/ANov 1, 2023Aalborg University
NCT05558462N/AAug 22, 2022Valenta Pharm JSC
NCT05294250Phase 1Feb 1, 2022Valenta Pharm JSC
NCT04676763N/AFeb 4, 2021GlaxoSmithKline
NCT04711044N/AFeb 1, 2021Aalborg University
Showing 20 of 57 trials
Page 1 / 3

Organizations

Research & Development (38)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Aalborg UniversityAcademic/Hospital242412018
Targeted Medical PharmaFor profit4422009
University of GothenburgAcademic/Hospital3122009
Valenta Pharm JSCFor profit3332022
EpiCept CorporationFor profit2022009
EURRUS Biotech GmbHFor profit2122016
Maxim PharmaceuticalsFor profit2211998
Pharmenterprises LLCFor profit2222015
University of California, Los AngelesAcademic/Hospital2022002
Amphastar PharmaceuticalsFor profit1112012
Andrews-Paulos Research & Education InstituteAcademic/Hospital1012012
ApimedsFor profit1112013
BioHealthonomics Inc.For profit1112015
Dynavax Technologies CorporationFor profit1112006
Free University of BrusselsAcademic/Hospital1112013
GlaxoSmithKlineFor profit1112021
Government of RussiaGovernment1112020
Groupe Francophone des MyelodysplasiesAcademic/Hospital1112011
Guangzhou Medical UniversityAcademic/Hospital1112012
Immune Tolerance NetworkAcademic/Hospital1012011
38 organizations
Page 1 / 2

Marketing (5)

OrganizationOrg typeRelationshipDate
ALK-Abello, S.A.For profitNDA2Sep 29, 1950
Eli LillyFor profitNDA2Apr 25, 1939
Jubilant Innovation Ltd.For profitNDA2Mar 13, 1924
Jubilant Innovation Ltd.For profitNDAMar 13, 1924
Nielsen BioSciences, Inc.For profitNDA2Feb 14, 1992